目的:评估华蟾素注射液肝动脉给药联合碘油栓塞对中晚期原发性肝癌患者中医证候特点的影响.方法:80例中晚期原发性肝癌患者随机分为华蟾素组和表阿霉素组.于介入治疗前及治疗后第6周,采用"中医肝病证候调查表"对两组患者的中医证候进行调查,并观察其单一症状出现频次及程度.结果:治疗前,两组气虚证、血瘀证、气滞证等评分及中医乏力、胁痛、大便干及小便黄等症状比较均无统计学差异.治疗后第6周,与表阿霉素组比较,华蟾素组气虚证、血瘀证、气滞证评分及乏力、胁痛、大便干、小便黄等显著变化(P＜0.05,P＜0.01).结论:华蟾素注射液肝动脉给药联合碘油栓塞治疗方案可改善中晚期原发性肝癌患者中医单证证候.

笔者在临床中应用加味四黄汤治疗各种难愈性皮肤溃疡,每有获效,报道如下:加味四黄汤组成:生大黄、黄连、黄柏、黄芩、蛇床子、紫草、千里光各50g、花椒15g,久煎浓缩,先熏洗后浸泡或浸透无菌纱布湿敷. 1 临床资料 例1:姚某,男性,65岁,患右下肢静脉曲张30余年,右下肢外侧皮肤溃烂1年余,于2010年就诊我院.

Primary liver cancer (PLC) is one of the most common malignant tumors because of its high incidence and high mortality. Traditional Chinese medicine (TCM) plays an active role in the treatment of PLC. As the most important part in the TCM system, syndrome differentiation based on the clinical manifestations from traditional four diagnostic methods has met great challenges and questions with the lack of statistical validation support. In this study, we provided evidences for TCM syndrome differentiation of PLC using the method of analysis of latent structural model from clinic data, thus providing basis for establishing TCM syndrome criteria. And also we obtain the common syndromes of PLC as well as their typical clinical manifestations, respectively.

朱德增教授认为感冒后咳嗽以感受风邪为主，不同发病季节，患者体质差异，可兼夹寒、热、燥、湿之邪为病，治疗以疏风宣散为主，兼以清热解毒、辛温散寒、生津润燥、化湿祛痰之法，升降并用，宣敛并施，以恢复肺洁净之性，宣降之功。

目的:探讨自拟中药止痛散外敷治疗晚期癌疼痛的疗效.方法:将122例患者随机分为对照组58例,治疗组64例,作疗效对比观察.对照组采用甘草粉加内科治疗;治疗组在内科常规保守治疗的基础上加用自拟止痛散外敷疼痛区,外敷4～6h/次,隔日1次,5次为1个疗程.结果:2组疗效对比,治疗组加用自拟中药止痛散,在缓解癌痛方面明显优于对照组.两者差异显著(P＜0.01).结论:中药止痛散采用“内病外治”,除在镇痛方面具有较好疗效外,也避免了内服药物造成的胃肠道反应.

Objective To evaluate the effect of transhepatic arterial embolization(TAE)with Cinobufotalin Injection on the quality of life(QOL)in patients with advanced primary liver cancer.Methods Eighty patients with advanced primary liver cancer were randomly divided into treatment group(n=40)and control group(n=40).The treatment group received TAE with Cinobufotalin Injection,while the control group received TAE with Epirubicin Injection.Before and 6weeks after TAE,the QOL was evaluated by Zubrod-ECOG-WHO(ZPS)score and Functional Assessment of Cancer Therapy-Hepatobiliary(FACTHep)questionnaire(Chinese version).Results Before treatment,there were no significant differences in ZPS score,FACT-Hep subscale scores,and total FACT-Hep score between the two groups(P0.05).At 6days after TAE,the treatment group showed a significant improvement in ZPS score(P0.01).At 6weeks after TAE,the treatment group had significantly higher FACT-Hep subscale scores and total FACT-Hep score than the control group(P0.05or P0.01).Conclusion Administration of Cinobufotalin Injection via the hepatic artery combined with lipiodol embolization can improve the QOL in patients with advanced primary liver cancer.